Health Care Professionals Log In

Sign up for Tygacil Updates

Registering for Wyeth.com is easy and gives you access to:

  • Wyeth Resources
  • Patient education
  • Literature and research
  • Visiting Speakers Bureau
  • eDetails
Register with Wyeth.com

TYGACIL has been reformulated to increase its stability once reconstituted and admixed. This reformulation also increased the Y-site compatibility of TYGACIL.

The following table provides more detail on reformulated TYGACIL, including vial contents, preparation and handling, storage guidelines for before and after reconstitution, and Y-site incompatibilities.

 

Characteristics TYGACIL Original Formulation TYGACIL Reformulation
NDC 0008-5360-021 0008-4990-021
Carton and Vial Description

Tygacil Box

Each TYGACIL vial contains 50 mg tygecycline lyophilized powder for intravenous infusion1

Tygacil Reformulation Box

Each TYGACIL vial contains 50 mg tigecycline lyophilized powder for intravenous infusion and 100 mg of lactose monohydrate. The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide1
Preparation and Handling
  • Reconstituted solution must be immediately withdrawn and added to an IV bag for infusion*1
  • TYGACIL may be stored in the IV bag at room temperature for up to 6 hours, or refrigerated at 2° to 8°C (36° to 46°F) for up to 24 hours1
  • Reconstituted solution may be stored at room temperature for up to 24 hours (up to 6 hours in the vial and the remaining time in the IV bag)1
  • TYGACIL may be stored refrigerated at 2° to 8°C (36° to 46°F) for up to 45 hours following immediate transfer of the reconstituted solution into the IV bag*1
Y-site Incompatibilites
  • Amphotericin B
  • Chlorpromazine
  • Methylprednisolone
  • Voriconazole1
  • Amphotericin B
  • Diazepam1

* Maximum concentration in the IV bag should be 1 mg/mL.

Next: Reconstitution and Administration »

Indications and Important Safety Information

Indications

TYGACIL® (tigecycline) is indicated for the treatment of adults with:

  • Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, and Bacteroides fragilis
  • Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros

Important Safety Information

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria
  • Anaphylaxis/anaphylactoid reactions have been reported with nearly all antibacterial agents, including tigecycline, and may be life-threatening
  • TYGACIL is contraindicated in patients with known hypersensitivity to tigecycline
  • TYGACIL should be administered with caution in patients with known hypersensitivity to tetracycline class antibiotics
  • Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis has been reported with the use of TYGACIL
  • The safety and efficacy of TYGACIL in patients with hospital-acquired pneumonia have not been established
  • In clinical trials, the most common treatment-emergent adverse events in patients treated with TYGACIL were nausea (29.5%) and vomiting (19.7%)
  • TYGACIL may cause fetal harm when administered to a pregnant woman
  • The safety and effectiveness of TYGACIL in patients below age 18 and lactating women have not been established
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis
  • Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective
  • The use of TYGACIL during tooth development may cause permanent discoloration of the teeth. TYGACIL should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated
  • Prothrombin time or other suitable anticoagulant test should be monitored if TYGACIL is administered with warfarin
  • Monotherapy should be used with caution in patients with clinically apparent intestinal perforation
  • In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours. Patients should be treated with caution and monitored for treatment response
  • The following drugs should not be administered simultaneously through the same Y‑site as TYGACIL: amphotericin B and diazepam

Please see Prescribing Information

205930-01